DREAMM-8: Patient-reported outcomes with belantamab mafodotin + Pd for RRMM

Results from the multicenter, phase III DREAMM-8 trial (NCT04484623) comparing patient-reported outcomes (PROs) with belantamab mafodotin + pomalidomide + dexamethasone (BPd, n = 155) vs pomalidomide + bortezomib + dexamethasone (PVd, n = 147) in 302 patients with relapsed/refractory multiple myeloma (RRMM) were recently published by Dimopoulos et al. in The Lancet Haematology. 

Key data: At a median follow-up of 21.8 months, health-related quality of life (HRQoL) remained stable over time in both groups. Between Weeks 5 and 53, meaningful improvement (≥10 points) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status/quality of life scores was more commonly observed in patients treated with BPd than PVd. Blurred vision was the adverse event (AE) most commonly reported as severe or very severe (43% in the BPd group vs 9% in the PVd group), followed by fatigue (38% vs 35%, respectively). Post hoc linear regression analysis suggested fatigue had the greatest negative impact on quality of life (QoL) measures while blurred vision had relatively minor effects.

Key learning: Belantamab mafodotin + Pd demonstrated manageable ocular toxicity with minimal impact on HRQoL, supporting its use for the treatment of RRMM despite higher rates of self-reported ocular events.